Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas.
In 81 patients with anaplastic supratentorial gliomas, single versus multiple chemotherapeutic agents were selected for treatment following surgery and during radiotherapy in a prospective randomized study. Time to treatment failure and survival were not significantly enhanced by multiple agent chemotherapy, as administered in this study.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D002330:Carmustine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005910:Glioma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D008936:Mitolactol / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011897:Random Allocation; D013713:Teniposide / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D011344:Procarbazine; D013713:Teniposide; D008936:Mitolactol; D002330:Carmustine; D008775:Methylprednisolone; D006918:Hydroxyurea